MA48798A - Procédé de production d'ozanimod - Google Patents

Procédé de production d'ozanimod

Info

Publication number
MA48798A
MA48798A MA048798A MA48798A MA48798A MA 48798 A MA48798 A MA 48798A MA 048798 A MA048798 A MA 048798A MA 48798 A MA48798 A MA 48798A MA 48798 A MA48798 A MA 48798A
Authority
MA
Morocco
Prior art keywords
ozanimod
production process
production
ozanimod production
Prior art date
Application number
MA048798A
Other languages
English (en)
Other versions
MA48798B1 (fr
Inventor
Judit Halász
Eniko Molnár
János Petho
Márta Porcs-Makkay
Gyula Simig
Éva Szabó
László Szlávik
Balázs Volk
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar
Publication of MA48798A publication Critical patent/MA48798A/fr
Publication of MA48798B1 publication Critical patent/MA48798B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA48798A 2017-05-22 2018-05-18 Procédé de production d'ozanimod MA48798B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1700216 2017-05-22
PCT/HU2018/050019 WO2018215807A1 (fr) 2017-05-22 2018-05-18 Procédé de production d'ozanimod

Publications (2)

Publication Number Publication Date
MA48798A true MA48798A (fr) 2020-04-08
MA48798B1 MA48798B1 (fr) 2023-10-31

Family

ID=89720175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48798A MA48798B1 (fr) 2017-05-22 2018-05-18 Procédé de production d'ozanimod

Country Status (12)

Country Link
US (1) US12459907B2 (fr)
EP (1) EP3630738B1 (fr)
CN (1) CN110997645B (fr)
EA (1) EA201992421A1 (fr)
ES (1) ES2960051T3 (fr)
HR (1) HRP20231308T1 (fr)
HU (1) HUE064642T2 (fr)
MA (1) MA48798B1 (fr)
PL (1) PL3630738T3 (fr)
PT (1) PT3630738T (fr)
SI (1) SI3630738T1 (fr)
WO (1) WO2018215807A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094409A1 (fr) * 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Sels et formes à l'état solide d'ozanimod
WO2020115200A1 (fr) * 2018-12-07 2020-06-11 Synthon B.V. Procédé amélioré pour la préparation d'ozanimod
WO2020152718A1 (fr) * 2019-01-25 2020-07-30 Mylan Laboratories Limited Formes polymorphes de 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyéthyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-méthyléthoxy)benzonitrile
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
US12404256B2 (en) 2019-07-16 2025-09-02 Synthon B.V. Process for preparing ozanimod
CA3156298A1 (fr) 2019-10-31 2021-05-06 Laetitia POUZOL Combinaison d'un antagoniste de cxcr7 avec un modulateur du recepteur s1p1
US12398112B2 (en) 2020-04-02 2025-08-26 Synthon B.V. Crystalline form of ozanimod hydrochloride
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2776242C (fr) 2009-10-08 2014-09-02 Sanofi Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds
PL2498610T5 (pl) 2009-11-13 2024-11-04 Receptos Llc Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
WO2015066515A1 (fr) * 2013-11-01 2015-05-07 Receptos, Inc. Modulateurs sélectifs des récepteurs de la sphingosine-1-phosphate et traitement combiné les utilisant
PL3470400T3 (pl) 2016-06-14 2025-08-04 Receptos Llc Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywania
CN109563059A (zh) * 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
WO2018049632A1 (fr) * 2016-09-14 2018-03-22 杭州领业医药科技有限公司 Forme cristalline d'ozanimod, procédé de préparation et composition pharmaceutique associés
CA3038106A1 (fr) * 2016-09-29 2018-04-05 Celgene International Ii Sarl Composes et methodes pour le traitement de l'inflammation

Also Published As

Publication number Publication date
US20200087269A1 (en) 2020-03-19
WO2018215807A1 (fr) 2018-11-29
PT3630738T (pt) 2023-10-24
EP3630738A1 (fr) 2020-04-08
HRP20231308T1 (hr) 2024-04-26
MA48798B1 (fr) 2023-10-31
EP3630738A4 (fr) 2021-03-10
HUE064642T2 (hu) 2024-04-28
US12459907B2 (en) 2025-11-04
ES2960051T3 (es) 2024-02-29
SI3630738T1 (sl) 2024-02-29
CN110997645A (zh) 2020-04-10
CN110997645B (zh) 2023-10-10
EA201992421A1 (ru) 2020-03-27
PL3630738T3 (pl) 2024-04-08
EP3630738B1 (fr) 2023-07-19

Similar Documents

Publication Publication Date Title
EP3702346A4 (fr) Procédé de production d'hexafluorobutadiène
MA50169A (fr) Procédé de production d'un électrocatalyseur
EP3378869A4 (fr) Procédé de production d'oligonucléotide
EP3630738A4 (fr) Procédé de production d'ozanimod
EP3578536A4 (fr) Procédé de production d'hydrocarbure fluorohalogéné
EP3613404A4 (fr) Procédé de production de film
EP3296282A4 (fr) Procédé de production d'hydrohalofluorooléfines
EP3354677A4 (fr) Procédé de production d'un copolymère de polycarbonate-polyorganosiloxane
EP3398957A4 (fr) Procédé de synthèse de l'ételcalcétide
EP3747624A4 (fr) Procédé de production de structure
EP3388390A4 (fr) Procédé de production d'ozone
EP3594250A4 (fr) Procédé de production de polymère
EP3327066A4 (fr) Procédé de production d'article coagulé
EP3734620A4 (fr) Procédé de production d'électrode transparente
EP3633713A4 (fr) Procédé de production d'une structure et structure
EP3704551A4 (fr) Procédé de production distribuée
EP3720845A4 (fr) Processus de production d'élagolix
EP3447042A4 (fr) Procédé de production de 1,2-dichlorohexafluorocyclopentène
EP3684757A4 (fr) Procédé de production d'alkylaromatiques
EP3778560A4 (fr) Procédé de production d'acrylonitrile
EP3659800A4 (fr) Procédé de production d'un stratifié
EP3831804A4 (fr) Procédé de production de 1-acyloxy-2-méthyl-2-propène
EP3689852A4 (fr) Procédé de production de dihydroxyindoles
EP3705473A4 (fr) Procédé de production de dihydroxyindoles
EP3640216A4 (fr) Procédé d'adsorption